Mariano Siguero

First-In-Human Phase I Study of Lurbinectedin (PM01183) in Patients with Advanced Solid Tumors

María Elena Elez, Josep Tabernero, David Geary et al. · Clinical Cancer Research · 2014 · 89 citations

Pharmacy, Oncology, Pharmacology +16

Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study

Emiliano Calvo, Víctor Moreno, Michael Flynn et al. · Annals of Oncology · 2017 · 85 citations · Full text

Medicine, Oncology, Pharmacology +12

Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment

Vivek Subbiah, Luis Paz‐Ares, Benjamin Besse et al. · Lung Cancer · 2020 · 38 citations · Full text

Medicine, Oncology, Pharmacology +14

Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study

Vivek Subbiah, Irene Braña, Alessandra Longhi et al. · Clinical Cancer Research · 2022 · 34 citations · Full text

Medicine, Oncology, Pharmacology +17

Efficacy and safety profile of lurbinectedin in second-line SCLC patients: Results from a phase II single-agent trial.

Luis Paz‐Ares, Jose M. Pérez, Benjamin Besse et al. · Journal of Clinical Oncology · 2019 · 25 citations

Medicine, Oncology, Pharmacology +14